A major breakthrough in the treatment of aHUS was a monoclonal antibody directed against the C5 component of the complement, eculizumab, which prevents the formation of C5a and C5b-9 components of the complement. This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.